Effects of hepatocyte growth factor overexpressed bone marrow-derived mesenchymal stem cells on prevention from left ventricular remodelling and functional improvement in infarcted rat hearts

Cell Biochemistry and Function

Volumn 30, Issue 7, 2012, Pages 574-581

  Wang, Shenxu ^a   Qin, Xing ^a   Sun, Dongdong ^a   Wang, Yunfang ^b   Xie, Xiaoyan ^b   Fan, Weiwei ^a   Wang, Yabin ^a   Liang, Dong ^a   Pei, Xuetao ^b   Cao, Feng ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Angiogenesis; Gene therapy; Hepatocyte growth factor; Mesenchymal stem cells; Myocardial infarction

Indexed keywords

AZACITIDINE; BETA1 INTEGRIN; BLOOD CLOTTING FACTOR 8; CD31 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CONNEXIN 43; DESMIN; EOSIN; HEMATOXYLIN; HERMES ANTIGEN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; SCATTER FACTOR; THY 1 ANTIGEN; TROPONIN I;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FUNCTIONAL STATUS; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; HEMODYNAMICS; HISTOLOGY; IN VITRO STUDY; MALE; MESENCHYMAL STEM CELL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; AZACITIDINE; BONE MARROW CELLS; CELLS, CULTURED; CORONARY VESSELS; DISEASE MODELS, ANIMAL; FEMALE; HEMODYNAMICS; HEPATOCYTE GROWTH FACTOR; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MYOCARDIAL INFARCTION; NEOVASCULARIZATION, PHYSIOLOGIC; RATS; RATS, WISTAR; TRANSFECTION; VENTRICULAR REMODELING;

RATTUS;

EID: 84866993025     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.2836     Document Type: Article

References (19)

1. Lavu M, Gundewar S, Lefer DJ. Gene therapy for ischemic heart disease. J Mol Cell Cardiol 2010; 50(5): 742-750.
2. Segers VF, Lee RT. Stem-cell therapy for cardiac disease. Nature 2008; 451(7181): 937-942.
3. Pittenger MF, Martin BJ. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res 2004; 95(1): 9-20.
4. Fedak PW. Paracrine effects of cell transplantation: modifying ventricular remodeling in the failing heart. Semin Thorac Cardiovasc Surg 2008; 20(2): 87-93.
5. Morishita R, Aoki M, Yo Y, Ogihara T. Hepatocyte growth factor as cardiovascular hormone: role of HGF in the pathogenesis of cardiovascular disease. Endocr J 2002; 49(3): 273-284.
6. Matsumori A, Furukawa Y, Hashimoto T, et al. Increased circulating hepatocyte growth factor in the early stage of acute myocardial infarction. Biochem Biophys Res Commun 1996; 221(2): 391-395.
7. Sato T, Yoshinouchi T, Sakamoto T, et al. Hepatocyte growth factor(HGF): a new biochemical marker for acute myocardial infarction. Heart Vessels 1997; 12(5): 241-246.
8. Deuse T, Peter C, Fedak PW, et al. Hepatocyte growth factor or vascular endothelial growth factor gene transfer maximizes mesenchymal stem cell-based myocardial salvage after acute myocardial infarction. Circulation 2009; 120(11 Suppl): S247-S254.
9. Ruvinov E, Leor J, Cohen S. The promotion of myocardial repair by the sequential delivery of IGF-1 and HGF from an injectable alginate biomaterial in a model of acute myocardial infarction. Biomaterials 2011; 32(2): 565-578.
10. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284(5411): 143-147.
11. Duan HF, Wu CT, Wu DL, et al. Treatment of myocardial ischemia with bone marrow-derived mesenchymal stem cells overexpressing hepatocyte growth factor. Mol Ther 2003; 8(3): 467-474.
12. Olivetti G, Capasso JM, Meggs LG, Sonnenblick EH, Anversa P. Cellular basis of chronic ventricular remodeling after myocardial infarction in rats. Circ Res 1991; 68(3): 856-869.
13. Li RK, Mickle DA, Weisel RD, Rao V, Jia ZQ. Optimal time for cardiomyocyte transplantation to maximize myocardial function after left ventricular injury. Ann Thorac Surg 2001; 72(6): 1957-1963.
14. Li Z, Gu TX, Zhang YH. Hepatocyte growth factor combined with insulin like growth factor-1 improves expression of GATA-4 in mesenchymal stem cells cocultured with cardiomyocytes. Chin Med J (Engl) 2008; 121(4): 336-340.
15. Hu X, Wang J, Chen J, et al. Optimal temporal delivery of bone marrow mesenchymal stem cells in rats with myocardial infarction. Eur J Cardiothorac Surg 2007; 31(3): 438-443.
16. Ueda H, Nakamura T, Matsumoto K, Sawa Y, Matsuda H. A potential cardioprotective role of hepatocyte growth factor in myocardial infarction in rats. Cardiovasc Res 2001; 51(1): 41-50.
17. Tang WH, Francis GS. The year in heart failure. J Am Coll Cardiol 2010; 55(7): 688-696.
18. Vogel S, Trapp T, Borger V, et al. Hepatocyte growth factor-mediated attraction of mesenchymal stem cells for apoptotic neuronal and cardiomyocytic cells. Cell Mol Life Sci 2010; 67(2): 295-303.
19. Kitta K, Day RM, Ikeda T, Suzuki YJ. Hepatocyte growth factor protects cardiac myocytes against oxidative stress-induced apoptosis. Free Radic Biol Med 2001; 31(7): 902-910.